Newswire (Published: Friday, December 1, 2017, Received: Tuesday, November 21, 2017, 1:49:14 PM CST)

Word Count: 439

Researchers from University of Southern California Describe Findings in Prostate Cancer (The evolution of chemotherapy for the treatment of prostate cancer)

By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating in Los Angeles, California, by NewsRx journalists, research stated, "Chemotherapy has been explored as a treatment option for metastatic prostate cancer since the early 1980s. Docetaxel, a taxane chemotherapeutic, was approved for the treatment of men with metastatic castration-resistant prostate cancer in 2004, and is now standard of care for late stage disease."

The news reporters obtained a quote from the research from the University of Southern California, "Recent clinical studies demonstrated that patients with metastatic castration-sensitive disease, and possibly those with high-risk localized prostate cancer also benefit from docetaxel administration, expanding the role of chemotherapy in the prostate cancer treatment landscape. Another taxane, cabazitaxel, is approved for post-docetaxel metastatic castration-resistant prostate cancer. Taxanes and other chemotherapeutics, such as carboplatin, are now being tested in combination regimens. This review presents an outline of recent and ongoing clinical studies assessing docetaxel and its derivative cabazitaxel at different stages of the disease, and in various combinations with other agents."

According to the news reporters, the research concluded: "We summarize current knowledge on biomarkers predictive of response to chemotherapy, which may in future be used to guide individualized treatment decisions."

For more information on this research see: The evolution of chemotherapy for the treatment of prostate cancer. Annals of Oncology, 2017;28(11):2658-2669. Annals of Oncology can be contacted at: Oxford Univ Press, Great Clarendon St, Oxford OX2 6DP, England. (Oxford University Press - www.oup.com/; Annals of Oncology - annonc.oxfordjournals.org)

Our news correspondents report that additional information may be obtained by contacting D.I. Quinn, Univ Southern Calif, Div Med Oncol, Norris Comprehens Canc Center, Los Angeles, CA 90033, United States. Additional authors for this research include H.M. Sandler, L.G. Horvath, A. Goldkorn and J.A. Eastham (see also Oncology - Prostate Cancer).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1093/annonc/mdx348. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Los Angeles, California, United States, North and Central America, Cancer, Article Review, Drugs and Therapies, Prostatic Neoplasms, Prostate Cancer, Chemotherapy, Oncology, University of Southern California.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

University of Southern California
Oxford University Press LLC

Places

Central America
North America
Northern Europe
United Kingdom
United States
Americas
Europe
England
California
Los Angeles

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies
            Chemotherapy